

To whom it may concern

Date: September 29<sup>th</sup>, 2025

Company Name : StemCell Institute Inc.

Representative : President Takafumi Shimizu

October 6 “World Cerebral Palsy Day”

Administration of sibling cord blood to a child with cerebral palsy

– Featuring a mother’s interview and research results from Kochi University –



10/6 世界脳性まひの日

さい帯血を保管&脳性まひの息子さんに投与された

お母さまへインタビュー

stemcell  
INSTITUTE

October 6, 2025 (Monday) marks “World Cerebral Palsy Day,” a day dedicated to promoting awareness and understanding of cerebral palsy worldwide. In Japan, about 1 in 1,000 to 6,000 children are diagnosed with cerebral palsy※1, often resulting from birth-related complications. As a lifelong motor function disorder, cerebral palsy requires consistent daily support from family members.

StemCell Institute Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Takafumi Shimizu, hereinafter “the Company”), which operates the “Cord Tissue & Cord Blood Family Bank” holding a 99% domestic market share, has conducted an interview with a family whose son, diagnosed with cerebral palsy, received cord blood stored at the Company. The resulting interview video has now been released.

※1 Clinical Study Protocol Number: jRCTa060200018 <https://jrct.mhlw.go.jp/latest-detail/jRCTa060200018>

## <Clinical Improvement After Sibling Cord Blood Transfusion: A Mother's Perspective on the Value of Cord Blood Storage>

Naomi Shibata, who lives in Kagoshima Prefecture, is a mother of three, including her eldest son, who has cerebral palsy. Thanks to having stored the cord blood of her daughters, she was able to participate in a clinical study at Kochi University and actually receive a sibling cord blood transfusion. After the transfusion, improvements were observed in her son's motor function and development. In an interview, she candidly shares her experience as a mother, accompanied by photos of her son.

<Interview Video with Ms. Shibata: <https://stemcell.co.jp/lp/movie/voice.mp4>>

### Video Highlights:

- The background on storing cord blood and participating in the clinical study
- Changes she observed in her child before and after the transfusion
- How the transfusion inspired her to establish a home-visit nursing station to support families in similar situations

## <Results from Domestic Clinical Research: Safety Confirmed and Potential Improvements in Motor Function and Development Suggested>

At Kochi University, the clinical study in which Ms. Shibata participated is investigating the administration of sibling-donated cord blood to children with cerebral palsy. Recently, a paper summarizing the results of this study※2 was published, confirming not only the safety of sibling cord blood transfusions but also suggesting the potential for clinical improvements in motor function and development. Additionally, the university has conducted earlier clinical research using children's own cord blood, which has also been reported in scientific publications. More information is available on our website, **HOPECELL NEWS**. These series of findings demonstrate the steady progress of clinical research in Japan and represent a significant step forward in exploring the new possibilities offered by cord blood.


※2 Safety and feasibility of allogeneic sibling cord blood infusion in Japanese children with cerebral palsy:

A single-center pilot study Brain & Development 47 (2025) 104443

## <Stem Cell Institute's Mission: Carrying Families' Hopes into the Future>

Our company holds a 99% domestic market share in cord tissue and cord blood storage, and we have entrusted with over 100,000 units to date. Leveraging a network of medical institutions built over more than 25 years and nationwide infrastructure, we are chosen by approximately 10,000 families every year.

Our mission is to carry families' precious hopes into the future. Through this communication, we aim to widely share the potential of cord blood research and its clinical applications, bringing hope and choices to as many people as possible.



※Cord Tissue Storage Service Launched in FY2022

## ■ StemCell Institute Inc.

With the corporate slogan “*Providing new medical care solutions for every new life*”, our company operates cell banking businesses for perinatal tissue-derived cells such as the “umbilical cord” and “cord blood,” leveraging a strong network with obstetrics and gynecology facilities. Our aim is to develop new therapies and products using these cells for regenerative and cell therapy purposes. Based on this business foundation, we strive for sustainable growth and social contribution by developing businesses and making investments in related fields such as regenerative medicine and femtech.

**Established:** August 5, 1999 (Listed on TSE Growth: 7096)

**Capital:** 704.8 million yen

**President & CEO:** Takafumi Shimizu

**Head Office:** 2F Tokyu Toranomon Building, 1-21-19 Toranomon, Minato-ku, Tokyo 105-0001

**TEL / Website:** 03-6811-3230 / <https://www.stemcell.co.jp/corporate/>

**Group Companies:** STEMCELL INNOVATIONS PTE. LTD. (Singapore), Milcare Co., Ltd.

**[For media inquiries regarding this announcement]**

**StemCell Institute Inc.**

Corporate Planning Division

TEL: 03-6811-3235 / MAIL: [ir@stemcell.co.jp](mailto:ir@stemcell.co.jp)